Abstracts tagged "calcinosis"

Abstract Number: 2053 • 2017 ACR/ARHP Annual Meeting
Computed Tomography Dependent Diagnosis of Crowned Dens Syndrome; A Cervical Manifestation of Patients with Calcium Pyrophosphate Dihydrate Crystal Deposition Disease
Ammar Haikal¹, Brian Everist², Pim Jetanalin³ and Mehrdad Maz³, ¹Department Internal Medicine, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, ²Department of Radiology (MSK), Department of Radiology (MSK), University of Kansas Medical Center, Kansas City, KS, ³Allergy, Clinical Immunology, and Rheumatology, Division of Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Crowned Dens Syndrome (CDS), a variation of Calcium Pyrophosphate Deposition Disease (CPPD), is a radiologic-clinical entity defined by the association of radiological calcifications around…
Abstract Number: 2137 • 2017 ACR/ARHP Annual Meeting
Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients
Vladislav Tsaltskan¹, Annette Aldous², Sam Serafi¹, Heidi Sami¹, Gulnara Mamyrova¹, Frederick W Miller³, Sam Simmens², Rodolfo Curiel¹, Olcay Y. Jones⁴ and Lisa G Rider³, ¹Department of Rheumatology, George Washington University, Washington, DC, ²Department of Epidemiology and Biostatistics, George Washington University Milken Institute School of Public Health, Washington, DC, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are rare, autoimmune chronic muscle diseases of childhood with significant potential long-term morbidity. In this study we investigate associations…
Abstract Number: 836 • 2016 ACR/ARHP Annual Meeting
Comprehensive Characterization of Calcinosis in a Multicenter International Cohort of Patients with Systemic Sclerosis
Antonia Valenzuela^1,2, Jessica K. Gordon³, Tatiana Sofia Rodriguez-Reyna⁴, Susanna Proudman^5,6, Murray Baron⁷, Monique Hinchcliff⁸, Dinesh Khanna⁹, Amber Young¹⁰, Flavia V. Castelino¹¹, Sara R. Schoenfeld¹², Virginia D. Steen¹³, David Fiorentino¹⁴ and Lorinda Chung¹⁵, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁶Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁷Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁸Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ¹¹Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹²Rheumatology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹³Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁴Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ¹⁵Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Calcinosis cutis is a debilitating complication of systemic sclerosis (SSc) affecting one quarter of patients. Repetitive trauma may be involved in the pathogenesis of…
Abstract Number: 841 • 2016 ACR/ARHP Annual Meeting
Low Nucleoside Triphosphate Pyrophosphohydrolase Activity Contributes to Pathologic Mineralization in Systemic Sclerosis
Yue Ding¹, Supraja Yeturi¹, Claudia Gohr¹, Mary Ellen Csuka¹ and Ann K. Rosenthal^2,3, ¹Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Medicine, Clement J. Zablocki VA Medical Center, Milwaukee, WI
Background/Purpose: Calcinosis is a major source of morbidity in patients with systemic sclerosis (SS). In addition, increased coronary calcification has been reported in patients with…
Abstract Number: 1898 • 2016 ACR/ARHP Annual Meeting
The Lack of Association of Osteoporosis with Proton Pump Inhibitor in Scleroderma: A UK Single Centre Cohort Experience
Ana Afonso¹, Svetlana Nihtyanova², Christopher Denton³ and Voon H. Ong⁴, ¹Internal Medicine, Hospital Pedro Hispano, EPE, Porto, Portugal, ²Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, Royal Free Hospital, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Rheumatology, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Recent studies suggest that proton pump inhibitor (PPI) use is variably associated with risk of osteoporosis. The aim of this study was to investigate…
Abstract Number: 830 • 2015 ACR/ARHP Annual Meeting
Calcinosis Is Associated with Digital Ulcers and Osteoporosis in Patients with Systemic Sclerosis
Antonia Valenzuela¹, Murray Baron², Ariane L. Herrick³, Susana Proudman⁴, Wendy Stevens⁵, Tatiana Sofia Rodriguez-Reyna⁶, Alessandra Vacca⁷, Thomas A. Medsger Jr.⁸, Monique Hinchcliff⁹, Vivien Hsu¹⁰, David Fiorentino¹¹, Lorinda Chung¹² and the Canadian Scleroderma Research Group, and the ASIG rubric, ¹Stanford University School of Medicine, Stanford, CA, ²Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴Rheumatology Unit, Royal Adelaide Hospital North Terrace, Adelaide, Australia, ⁵Department of Rheumatology, St. Vincent’s Hospital Melbourne, Melbourne, Australia, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷University Hospital of Cagliari, Rheumatology Unit, Monserrato, Italy, ⁸Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology, Northwestern University, Chicago, IL, ¹⁰Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ¹¹Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ¹²Stanford University, Palo Alto, CA
Background/Purpose: Calcinosis is a debilitating complication of systemic sclerosis (SSc). We sought to determine the clinical factors associated with calcinosis in an international multi-center collaborative…
Abstract Number: 1898 • 2015 ACR/ARHP Annual Meeting
Are There Risk Factors for Calcinosis in Scleroderma?
Sneha Pai¹ and Vivien Hsu², ¹Rheumatology, Robert Wood Johnson Medical School Hospital, New Brunswick, NJ, ²Medicine, Rutgers University, New Brunswick, NJ
Background/Purpose: Calcinosis is the deposition of calcium hydroxyapatite in the soft tissues in patients with scleroderma spectrum disorders (SSc). Risk factors are unknown and there…
Abstract Number: 1904 • 2015 ACR/ARHP Annual Meeting
Development of the Mawdsley Calcinosis Questionnaire (MCQ) Version 1 – a Patient-Reported Outcome Measure (PROM) for Systemic Sclerosis Related Calcinosis (SSc-Ca)
Lesley Ann Saketkoo¹, Kim Fligelstone², Evan Busman³, Angela Christensen⁴, Sophia Cenac⁵, Samara Khalique⁶, Andrew Aubin⁷, Veronika K. Jaeger⁸, Anne Mawdsley⁹, Jessica K. Gordon¹⁰, Randi Kaufman¹¹, Murray Baron¹², Virginia D. Steen¹³ and Tracy M. Frech¹⁴, ¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ³Atlanta Scleroderma Support Group, Atlanta, GA, ⁴Tulane University School of Medicine, New Orleans, LA, ⁵Louisiana State University Health Science Center, New Orleans, LA, ⁶Louisiana State University Health Sciences Center, New Orleans, LA, ⁷Louisiana State University School of Medicine, New Orleans, LA, ⁸Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁹Raynaud's & Scleroderma - Care and Support UK, Cheshire, United Kingdom, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Lousiana State University Health Sciences Center - School of Public Health, New Orleans, LA, ¹²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ¹³Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁴Div of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: SSc-Ca is a poorly understood vascular complication of SSc that usually related to extreme constant pain and infection/amputation risk for persons living with SSc-Ca…
Abstract Number: 2037 • 2015 ACR/ARHP Annual Meeting
Rheumatic Manifestations May be the First Clinical Presentation of Arterial Calcification Due to CD73 Deficiency
Kam Newman¹, megha Sawhney², James D. Katz³, richard siegel⁴, alessandra brofferio⁵ and Manfred Boehm⁶, ¹national institutes of arthritis, musculoskeletal, and skin disease, National Institutes of Health, Bethesda, MD, ²national institutes of health, Bethesda, MD, ³Department of Medicine, Division of Rheumatology, The George Washington University, Washington, DC, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵national institutes of health, Bethesda,, MD, ⁶Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: ACDC is a hereditary ectopic mineralization syndrome caused by mutations in the NT5E gene that encodes CD73. CD73 is a membrane bound 5'…
Abstract Number: 2369 • 2015 ACR/ARHP Annual Meeting
Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: A Longitudinal Analysis
Matthew Lewis¹, Shufeng Li¹, Lorinda Chung² and David Fiorentino¹, ¹Dermatology, Stanford University, Stanford, CA, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Dermatomyositis (DM) patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are at increased risk of developing interstitial lung disease (ILD). The natural history of…
Abstract Number: 2960 • 2015 ACR/ARHP Annual Meeting
Sodium Thiosulfate in Calcinosis
Eliza Pelrine¹, Jessica K. Gordon², Murray Baron³ and Robert F. Spiera², ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Calcinosis occurs in ~25% of patients with Systemic Sclerosis (SSc) and causes pain, morbidity, and decreased quality of life. The treatment of calcinosis is…
Abstract Number: 2707 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Related Calcinosis: Patients Provide What Specialists Want to Learn
Angela Christensen¹, Samara Khalique², Sophia Cenac³, Kim Fligelstone⁴, Anne Mawdsley⁵, Tracy Frech⁶, Jessica K. Gordon⁷, Murray Baron⁸, Evan Busman⁹, Virginia D. Steen¹⁰ and Lesley Ann Saketkoo¹¹, ¹Tulane University School of Medicine, New Orleans, LA, ²Louisiana State University Health Sciences Center, New Orleans, LA, ³Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Raynaud's & Scleroderma - Care and Support UK, Cheshire, United Kingdom, ⁶Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, ⁹Atlanta Scleroderma Support Group, Atlanta, GA, ¹⁰Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹¹Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Calcinosis is a disabling, rarely discussed manifestation of SSc for which the natural history and management is poorly understood. Last year, the Scleroderma Clinical…
Abstract Number: 2191 • 2014 ACR/ARHP Annual Meeting
Intravenous Sodium Thiosulfate for Treatment of Refractory Calcinosis in Rheumatic Disease
Ross Thibodaux¹, Bahnsen Miller¹ and Stephen Lindsey^2,3, ¹Internal Medicine, Louisiana State University Health Science Center, Baton Rouge, LA, ²Chief Div of Rheumatology, Ochsner Clinic Baton Rouge, Baton Rouge, LA, ³Internal Medicine - Rheumatology, Louisiana State University Health Science Center, Baton Rouge, LA
Background/Purpose: Calcinosis, or dystrophic calcification, is a poorly understood, debilitating condition commonly manifested in connective tissue diseases such as scleroderma and polymyositis. Despite treatment of…
Abstract Number: 1926 • 2014 ACR/ARHP Annual Meeting
Nailfold Videocapillaroscopy Patterns Associated with Calcinosis and Acro-Osteolysis in Systemic Sclerosis
Jerome Avouac¹, Laetitia Morardet², Maya Sammour³, Andre Kahan², Antoine Feydy³ and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ³Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France
Background/Purpose: Calcinosis and acro-osteolysis are frequent in systemic sclerosis (SSc). They may be related to digital vasculopathy, which can be assessed by nailfold videocapillaroscopy (NVC).…
Abstract Number: 1315 • 2014 ACR/ARHP Annual Meeting
Cross-Sectional Evaluation of Hydroxychloroquine (HCQ) Therapy in Children with Juvenile Dermatomyositis (JDM) Enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Yonit Sterba¹, Dawn Wahezi² and For the CARRA investigators³, ¹Pediatric Rheumatology, Montefiore Medical Center, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Duke Children's Hospital, Durham, NC
Background/Purpose: Hydroxychloroquine is an antimalarial agent commonly used in the treatment of rheumatologic diseases. Data on the use of HCQ in JDM is limited, primarily…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].